Clinical trial · Interventional
Comparing Interleukin-2 (IL-2) Combined With Rituximab (Rituxan) to Rituximab Alone in Subjects With Non-Hodgkin's Lymphoma (NHL)
A Phase 2 Randomized, Open-Label, Controlled Trial of the Addition of 8 Weeks SC Administration of Aldesleukin (Rh-Interleukin-2 [IL-2]) to 4 Weeks of IV Administration of Rituximab in the Treatment of Rituximab Naïve Subjects With Follicular Non-Hodgkin's Lymphoma, Refractory or Relapsed After Previous Chemotherapy
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to determine whether interleukin-2 given 3 times weekly for 8 weeks in combination with rituximab is effective and safe when compared to rituximab given alone in the treatment of follicular NHL subjects that have never received rituximab as a treatment and are refractory or relapsed after previous chemotherapy.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Non-Hodgkin Lymphoma | Non-Hodgkin Lymphoma | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| interleukin-2 | Drug | Aldesleukin | ALIAS |
| rituximab | Drug | Rituximab | ALIAS |
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * CD20+ follicular B-cell non-hodgkin's lymphoma with at least 1 site of measurable disease. * Previous treatment with 1 to 4 prior chemotherapy regimens * ECOG performance status of greater than or equal to 2 * Life expectancy of greater than 18 weeks * Meet safety lab requirements and organ function tests Exclusion Criteria: * Prior treatment with rituximab or IL-2 * Prior radioimmunotherapy including Zevalin or Bexxar * 5 or more prior chemotherapy regimens * Clinically significant cardiac disease, lung dysfunction, autoimmune disease, thyroid disease, active infection, unstable psychiatric condition, or HIV infection. * History of allogenic bone marrow transplant * Female subjects that are pregnant or breast feeding * Immunosuppressive therapy including corticosteroids or investigational agents within 4 weeks prior to the planned start of study treatment
References
Publications (0)
Data not yet available